Bone Biologics (BBLG) Other Non-Current Liabilities (2022 - 2026)
Bone Biologics (BBLG) posted quarterly Other Non-Current Liabilities of $703.0 for Q4 2025, down 84.95% year-over-year from $4670.0 in Q4 2024, and down 41.47% quarter-over-quarter from $1201.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Other Non-Current Liabilities for 4 consecutive years, with $703.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 84.95% year-over-year to $703.0; the TTM figure through Dec 2025 stood at $703.0 (down 84.95% YoY), while the FY2025 annual figure was $703.0, down 84.95% from the prior year.
- Other Non-Current Liabilities fell to $703.0 in Q4 2025 per BBLG's latest filing, from $1201.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q1 2023 and bottomed at $703.0 in Q4 2025.
- Historically, Other Non-Current Liabilities has averaged $294236.8 across 4 years, with a median of $17629.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities tumbled 98.94% — and 2025, when it plunged 68.48%.
- Bone Biologics' Other Non-Current Liabilities stood at $1.7 million in 2022, then sank by 96.64% to $55751.0 in 2023, then sank by 91.62% to $4670.0 in 2024, then tumbled by 84.95% to $703.0 in 2025.
- Business Quant data shows BBLG's Other Non-Current Liabilities at $703.0 in Q4 2025, $1201.0 in Q3 2025, and $2413.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 546.00 |
| Dec 31, 2025 | 703.00 |
| Sep 30, 2025 | 1,201.00 |
| Jun 30, 2025 | 2,413.00 |
| Mar 31, 2025 | 3,315.00 |
| Dec 31, 2024 | 4,670.00 |
| Sep 30, 2024 | 17,629.00 |
| Jun 30, 2024 | 7,655.00 |
| Mar 31, 2024 | 18,440.00 |
| Dec 31, 2023 | 55,751.00 |
| Sep 30, 2023 | 80,514.00 |
| Jun 30, 2023 | 241,160.00 |
| Mar 31, 2023 | 1.73 Mn |
| Dec 31, 2022 | 1.66 Mn |